Akèy › Limfom Difize Gwo Selil B › Virginia › Richmond
Etid klinik pou Limfom Difize Gwo Selil B nan Richmond, VA
10 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Richmond (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- VCU Massey Comprehensive Cancer Center, Richmond
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Virginia Commonwealth University Massey Cancer Center, Richmond
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Virginia Cancer Institute ( Site 0148), Richmond
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- Massey Cancer Center, Richmond
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Virginia Commonwealth University-Massey Cancer Center, Richmond
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- VCU Massey Comprehensive Cancer Center, Richmond
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Ap rekriteFaz 2
- Virginia Commonwealth University, Richmond
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Houston, TX17 etid
- Los Angeles, CA17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Nashville, TN15 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
Lòt etid nan Richmond
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil25 etid
- Kansè pwostat19 etid
- Ensifizyans kadyak16 etid
- Kansè poumon14 etid
- Kansè kolorektal13 etid
- Maladi kadyovaskilè13 etid
- Maladi fwa steatotik12 etid
- Leksemi mieloïd egi12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
- Kansè Metastatik12 etid
- Melanom11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 4, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.